Bulletin of Experimental Biology and Medicine

, Volume 139, Issue 6, pp 721–723 | Cite as

Metformin Decelerates Aging and Development of Mammary Tumors in HER-2/neu Transgenic Mice

  • V. N. AnisimovEmail author
  • P. A. Egormin
  • L. M. Bershtein
  • M. A. Zabezhinskii
  • T. S. Piskunova
  • I. G. Popovich
  • A. V. Semenchenko


Transgenic FVB/N female mice carrying HER-2/neu mammary cancer gene received metformin (1200 mg/liter) with drinking water 5 days a week starting from the age of 2 months until natural death. Metformin slightly reduced food consumption, but did not change water consumption and dynamics of weight gain. Mean life span of mice increased by 8% (p<0.05), in 10% long-living mice it was prolonged by 13.1%, and the maximum life span was prolonged by 1 month under the effect of metformin in comparison with the control. The rate of populational aging decreased by 2.26 times. The total incidence of mammary adenocarcinoma and their multiplicity did not change under the effect of metformin, while the latency of tumor development increased and the mean diameter of tumors decreased. Hence, we first demonstrated a geroprotective effect of metformin and its suppressive effect towards the development of mammary tumors.

Key Words

metformin life span breast cancer transgenic mice HER-2/neu 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    V. N. Anisimov, Molecular and Physiological Mechanisms of Aging [in Russian], St. Petersburg (2003).Google Scholar
  2. 2.
    L. M. Bershtein, Oncoendocrinology. Traditions, State of the Art, Prospects [in Russian], St. Petersburg (2004).Google Scholar
  3. 3.
    A. I. Bozhkov, Uspekhi Gerontol., 8, 89–99 (2001).Google Scholar
  4. 4.
    E. V. Gubler, Computation Methods of Analysis and Recognition of Pathological Processes [in Russian], Leningrad (1978).Google Scholar
  5. 5.
    V. N. Anisimov, Exp. Gerontol., 38, No.10, 1041–1049 (2003).CrossRefPubMedGoogle Scholar
  6. 6.
    V. V. Bakaev, Biogerontology, 3,Suppl. 1, 23–24 (2002).Google Scholar
  7. 7.
    D. R. Cox and D. Oakes, Analysis of Survival Data, London (1996).Google Scholar
  8. 8.
    V. M. Dilman and V. N. Anisimov, Gerontology, 26, No.5, 241–245 (1980).PubMedGoogle Scholar
  9. 9.
    V. M. Dilman, L. M. Bershtein, M. A. Zabezhinski, et al., Arch. Geschwulforsch., 48, No.1, 1–8 (1978).Google Scholar
  10. 10.
    F. S. Facchini, N. W. Hua, G. M. Reaven, and R. A. Stoohs, Free Radic. Biol. Med., 29, No.12, 1302–1306 (2000).CrossRefPubMedGoogle Scholar
  11. 11.
    E. J. Masoro, Exp. Gerontol., 35, 299–305 (2000).CrossRefPubMedGoogle Scholar
  12. 12.
    M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, Nat. Rev. Cancer, 4, No.7, 505–518 (2004).CrossRefPubMedGoogle Scholar
  13. 13.
    S. R. Spindler, J. D. Dhahbi, P. L. Mote, et al., Biogerontology, 4,Suppl. 1, 89 (2003).Google Scholar
  14. 14.
    R. Weindruch, K. P. Keenan, J. M. Carney, et al., J. Gerontol. Biol. Sci., 56 A, Special Issue 1, 20–33 (2001).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • V. N. Anisimov
    • 1
    Email author
  • P. A. Egormin
    • 1
  • L. M. Bershtein
    • 1
  • M. A. Zabezhinskii
    • 1
  • T. S. Piskunova
    • 1
  • I. G. Popovich
    • 1
  • A. V. Semenchenko
    • 2
  1. 1.Prof. N. N. Petrov Institute of OncologyMinistry of Health of the Russian FederationSt. PetersburgRussia
  2. 2.Institute of Demographic StudiesMax Plank SocietyRostokGermany

Personalised recommendations